LOGO_%E5%B7%A5%E4%BD%9C%E5%8D%80%E5%9F%9F%201%20%E8%A4%87%E6%9C%AC%204.png)
Corporate Overview | ABOUT US
Exxon’s senior team members have professional backgrounds covering international technology, natural medicine, biotechnology, cultural creation,
Banking investment, etc., through the joint assistance of business partners across various industries, to the road to success, successfully leading the IPO of Lianya Pharmaceuticals, and providing excellent investment returns for fund shareholders and investors.
- U.S. FDA approved injection production line
- U.S. FDA approved ointment production line
- Japan PMDA approved injection production line
- Colombia INVIMA approved soft cream production line
- Australia TGA approved soft cream production line
- Taiwan's Ministry of Health and Welfare TFDA approved drug/regulated drug production line
Novartis, J&J, Astellas, GSK, Sanofi, Pfizer, Aspen MSD, Daichi-Sankyo, etc.
In 2019, the U.S. special injection generic drug market is about
US$11.7 billion, a compound annual growth rate of 14.9%.
With the increasingly stringent international pharmaceutical regulations, many American injection factories have been closed because they cannot meet the latest regulatory requirements (according to statistics, 60% of warning letters are issued to injection factories). In the US drug shortage incidents, the shortage of injection medicine accounts for the majority (70%). % out of 102 shortage in 2018). Therefore, it is a big niche to enter the US special injection market through the existing FDA-approved injection product line.
